source: http://online.wsj.com/article/SB10001424052748703571704575340880052218588.html

NEW YORK—Arena Pharmaceuticals Inc. signed a deal for Japanese drug maker Eisai Co. to sell experimental weight-loss drug lorcaserin in the U.S., if it is approved by the Food and Drug Administration.

The deal, the value of which largely rests upon the commercial success of lorcaserin, came earlier than expected as investors await the FDA’s reaction to new weight-loss treatments. Arena, which will face an FDA panel in September and a decision by late October, is vying against Orexigen Therapeutics Inc. and Vivus Inc. to develop a new obesity treatment in the U.S.

Related posts:

1. Orexigen, Takeda in $1 bln deal for obesity drug
2. Arena Gets $100M Loan
3. Stem Cells to be a Central Track at GTCbio’s 5th Annual Modern Drug Discovery & Development Conference Held on October 14-16, 2009 in San Diego, CA
4. 3 biotech startups in San Diego raise funding for new drug development
5. Celgene to buy Abraxis for $2.9B in biotech deal